Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration-Reference-Cited by-同舟云学术

Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration

Published:2023-02-01 Issue:2 Volume:46 Page:194-200
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Nakagawa Shunsaku¹,Shimazaki Aimi¹,Funakoshi Taro²,Yonezawa Atsushi¹,Kataoka Shigeki²,Horimatsu Takahiro²,Hira Daiki¹,Itohara Kotaro¹,Imai Satoshi¹,Nakagawa Takayuki¹,Matsubara Takeshi³,Yanagita Motoko³,Muto Manabu²,Matsubara Kazuo⁴,Terada Tomohiro¹

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital

2. Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University

3. Department of Nephrology, Graduate School of Medicine, Kyoto University

4. Department of Pharmacy, Wakayama Medical University Hospital

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/46/2/46_b22-00578/_pdf

Reference28 articles.

1. 1) Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother. Pharmacol., 75, 495–503 (2015).

2. 2) Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother. Pharmacol., 45, 157–164 (2000).

3. 3) Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J. Clin. Oncol., 21, 2664–2672 (2003).

4. 4) Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin. Cancer Res., 13, 4832–4839 (2007).

5. 5) Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Relationship between renal function and the incidence of adverse events in patients with colorectal cancer receiving oxaliplatin. Anticancer Res., 40, 299–304 (2020).